

Gag-specific CD4 T-cell proliferation, plasmacytoid dendritic cells and ethnicity in perinatally HIV-1-infected youths – The ANRS-EP38-IMMIP Study Short title: T-cell proliferation and dendritic cells

Daniel Scott-Algara, Josiane Warszawski, Jérôme Le Chenadec, Céline Didier, Thomas Montange, Jean-Paul Viard, Catherine Dollfus, Véronique Avettand-Fenoel, Christine Rouzioux, Stéphane Blanche, et al.

► **To cite this version:**

Daniel Scott-Algara, Josiane Warszawski, Jérôme Le Chenadec, Céline Didier, Thomas Montange, et al.. Gag-specific CD4 T-cell proliferation, plasmacytoid dendritic cells and ethnicity in perinatally HIV-1-infected youths – The ANRS-EP38-IMMIP Study Short title: T-cell proliferation and dendritic cells. *AIDS Research and Human Retroviruses*, Mary Ann Liebert, 2016, 33 (1), pp.21-28. <10.1089/aid.2016.0177>. <pasteur-01416596>

HAL Id: pasteur-01416596

<https://hal-pasteur.archives-ouvertes.fr/pasteur-01416596>

Submitted on 14 Dec 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Gag-specific CD4 T-cell proliferation, plasmacytoid dendritic cells and ethnicity in perinatally HIV-1-infected youths – The ANRS-EP38-IMMIP Study

Short title: T-cell proliferation and dendritic cells

Daniel SCOTT-ALGARA¹, Josiane WARSZAWSKI^{2,3}, Jérôme LE CHENADEC²,
Céline DIDIER⁴, Thomas MONTANGE^{5,6}, Jean-Paul VIARD^{7,8}, Catherine DOLLFUS⁹,
Véronique AVETTAND-FENOEL^{7,10}, Christine ROUZIOUX^{7,10}, Stéphane BLANCHE¹¹,
Florence BUSEYNE^{5,6,8}

¹ Institut Pasteur, Unité Cytokines et Inflammation, Paris, France

² CESP INSERM U1018, Le Kremlin-Bicêtre, France

³ Université Paris-Sud, Le Kremlin-Bicêtre, France

⁴ Institut Pasteur, Groupe Mécanismes de l'Hérédité Epigénétique, Paris, France

⁵ Institut Pasteur, Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes,
Paris, France

⁶ CNRS, UMR 3569, Paris, France

⁷ EA7327, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine,
Paris, France

⁸ AP-HP, Centre de Diagnostic et de Thérapeutique, Hôpital de l'Hôtel-Dieu, Paris,
France

⁹ AP-HP, Service d'Hématologie et d'Oncologie Pédiatrique, Hôpital Trousseau,
Paris, France

¹⁰ AP-HP, Laboratoire de Virologie, Hôpital Necker-Enfants Malades, Paris, France

¹¹ AP-HP, Unité Immunologie et Hématologie Pédiatrique, Hôpital Necker-Enfants
Malades, Paris, France

§ Address correspondence to Florence Buseyne, Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, 28 rue du Dr Roux, 75015 Paris, France. florence.buseyne@pasteur.fr fax:+33 1 40 61 34 65; tel +33 1 45 68 88 99.

Keywords: perinatal HIV infection, youths, T-cell proliferation, dendritic cells, sCD14, CD4 T cells

Abstract

In perinatally HIV-1-infected youths living in France, we previously reported that Gag-specific CD4 and CD8 T-cell proliferation is more frequently detected in patients of black ethnicity than in those of other ethnicities. We observed that black patients had higher levels of dendritic cells than other patients. We aimed to study the association of dendritic cell levels with Gag-specific T-cell proliferation. The ANRS-EP38-IMMIP study is an observational study of youths aged between 15 and 24 years who were perinatally infected with HIV. A single blood sample was drawn for virological and immunological assays. Data from cART treated 53 youths with undetectable plasma HIV RNA were analyzed. Gag-specific T-cell proliferation was assessed using a CFSE-based test. Peripheral blood myeloid and plasmacytoid dendritic cells (mDCs and pDCs) were phenotyped by flow cytometry. Plasma markers were quantified by ELISA or multiplex assays. Logistic regression was used for univariate and multivariate analyses. Patients with Gag-specific CD4 T-cell proliferative responses had significantly higher percentages and absolute counts of mDCs and pDCs in the peripheral blood than nonresponding patients. Gag-specific CD4 and CD8 T-cell proliferation were associated with lower plasma sCD14 levels. Plasma levels of IFN- α , TRAIL and chemokines involved in T-cell migration to secondary lymphoid organs were not associated with T-cell proliferation. Multivariate analysis confirmed the association between Gag-specific CD4 T-cell proliferation and pDC levels. In conclusion, dendritic cell levels are a robust correlate of the presence of Gag-specific T-cell proliferation in successfully treated youths.

Introduction

HIV-specific T cells are important correlates of viral control and delayed disease progression in untreated individuals and may play an important role in future strategies targeting the viral reservoir¹. Understanding their restoration and maintenance is important, especially in patients with a perinatally-acquired infection whose immune system developed in the presence of active HIV-1 replication. We previously reported that Gag-specific CD4 and CD8 T-cell proliferation was more frequently detected in youths of black ethnicity than in those of other ethnicities². These differences in T-cell responses were observed for youths born in the same country, France, with similar routes of HIV infection, similar access to health care and whose immune systems were subjected to a similar environmental infectious pressure during their entire life. These patients offer a unique opportunity to characterize ethnicity-related differences in immune restoration, without the confounding effects usually associated with the study of people of diverse geographic origins.

We observed that the levels of myeloid cells and related plasma markers differed between black patients and patients from other ethnic groups. Dendritic cells affect T-cell responses through antigen presentation, secretion of pro-inflammatory molecules, and transmission of HIV particles to susceptible target cells³. Thus, we aimed here to study the association between dendritic cells and Gag-specific T-cell proliferation, focusing on patients with undetectable plasma HIV RNA at the time of the study.

Materials and methods

Patients

The ANRS-EP38-IMMIP study included 93 patients who acquired HIV-1 infection during the perinatal period and were at least 15 years old at the time of the study^{4,5}. The study was approved by the local ethics committees. All patients, and their legal guardians for those under 18 years of age, received written information and signed an informed consent form. This study was approved by the “Comité de protection des personnes Ile-de-France II” (registration number 06-09-08), authorized by the “Direction Générale de la Santé” (authorization number 2006-AOO142-49). The ANRS-EP38-IMMIP study is registered as an observational study at www.clinicaltrials.gov under identifier NCT01055873. A single blood sample was drawn for virological and immunological assays. At the time of the study, the threshold values used in HIV RNA assays depended on the volume of plasma available. The highest threshold used was 80 copies/mL, and this value was selected as the cutoff for current HIV RNA detection, as described⁴. The cutoff of 500 copies/mL was chosen for assessments of virological history, because of changes in HIV RNA quantification assays over time.

Biological analyses

Freshly isolated peripheral blood mononuclear cells (PBMCs) were labeled with 10 μ M CFSE (5-6-carboxyfluorescein diacetate succinimidyl ester) and stimulated with pools of Gag peptides (NIH #8117). Six days later, the cells were labeled with a combination of anti-CD3-ECD, anti-CD4-PC7, and anti-CD8 β -PC5 antibodies (Beckman Coulter, Villepinte, France), and analyzed on a FC500 flow cytometer (Beckman Coulter). CFSE^{low} T cells were quantified for CD4 and CD8 T-cell subpopulations (see² for gating strategy). Assays were scored positive if the difference in the percentages of CFSE^{low} cells between antigen-stimulated and mock-stimulated cells was above 0.8% and the ratio of these percentages was above 4. This dual criterion cutoff was based on assays performed with uninfected donors, as described². Patients with positive results in the Gag-specific CD4 T-cell assay are referred to

as CD4 responders (CD4Rs) and those with negative results for this assay are referred to as CD4 nonresponders (CD4NRs). Similarly, CD8Rs and CD8NRs are defined on the basis of the results of the Gag-specific CD8 T-cell proliferation assay. CD4 T-cell percentages and CD4 T-cell and monocyte counts were determined at the clinical sites as part of the standard follow-up procedure. Myeloid and plasmacytoid dendritic cells (mDCs and pDCs) were studied with a combination of labeled antibodies: FITC-anti-CD14, FITC-anti-CD16, PE-anti-CD85k, PC5-anti-CD33, PC7-anti-CD123 (Fig. 1) ^{6, 7}. Results were available for 42 patients. Patients with and without dendritic cell data were similar regarding age, CD4 T-cell count, cell-associated HIV DNA levels, time spent with an HIV RNA level < 500 copies and time spent on HAART (data not shown). Plasma samples from 52 out of 53 patients were assayed for cytokines, chemokines and sCD14, according to the manufacturer's instructions for each kit (references and quantification thresholds are presented in Supplementary Table 1).

Statistical analysis

Associations between ethnicity and immune parameters were assessed using the Fisher's exact test and the Mann-Whitney test for qualitative and quantitative variables, respectively. Patients were classified according to the detection of Gag-specific CD4 and CD8 T-cell proliferation. Logistic regression was used for univariate and multivariate analyses of data. We took ethnic origin into account, by grouping patients originating from sub-Saharan Africa and the Caribbean and comparing them with those of other geographic origins (mainland France, North Africa and Asia). The patients are referred to as being of black or other ethnicity. Phylogenetic analyses were carried out on the sequences of the *Env* and *RT* genes, to determine virus subtype, as described in ². The analyses were exploratory and were, therefore, not corrected for multiple testing. For variables associated with Gag-specific T-cell proliferation with a *P* value ≤ 0.20 in univariate analysis, we tested the associations with inclusion of demographic and HIV disease history variables previously found to be associated with T-cell proliferation ². We did not build a model with all immunological parameters, as

these were not quantified for all patients, due to a lack of available samples for some of them. Analyses were conducted using SAS software (version 9.2). A *P* value of <0.05 was considered to indicate statistical significance.

Results

Patients

The analyses described here were restricted to the 53 patients who were receiving highly active antiretroviral treatment (HAART) and had undetectable plasma HIV RNA at the time of the study, and for whom a valid proliferation assay had been carried out. Twenty-four of the patients were male, and 19 were of black ethnicity. At the time of the study, the median age of the patients was 18 years (interquartile range (IQR): 16-19 years), patients had been on HAART for a median cumulative duration of 9.1 years (IQR: 7.6-9.8 years), had a median CD4 T-cell count of 635 cells/ μ l (IQR: 522-918 cells/ μ l) and a median duration of HIV RNA < 500 copies/ml of 3.0 years (IQR: 1.3-6.3 years).

Gag-specific CD4 T-cell proliferation is associated with higher peripheral blood dendritic cell levels

Black patients had higher percentages and absolute counts of mDCs than patients of other ethnic groups (Table 1). They tended to have higher percentages of pDCs and lower monocyte counts. We compared the levels of these antigen-presenting cells (APCs) between patients with and without Gag-specific CD4 T-cell proliferation (CD4Rs and CD4NRs, respectively). Data are presented for the two ethnic groups in Fig. 2 and results from the logistic regression are reported in panels J-K. CD4Rs had significantly higher percentages and absolute counts of mDCs and pDCs in the peripheral blood than CD4NRs (Fig. 2A-D). The peripheral blood monocyte count was not associated with Gag-specific CD4 T-cell proliferation (Fig. 2E). Gag-specific CD4 T-cell proliferation was associated with the percentage and absolute count of pDC after adjustment for ethnicity (Fig. 2K). Inclusion of the HIV subtype in the multivariate analysis did not modify the associations (data not shown).

Gag-specific CD4 T-cell proliferation tends to be associated with lower plasma sCD14 levels

We then quantified plasma markers related to APC activation (sCD14, neopterin, and CCL2), and type I IFN production (IFN- α and TRAIL) because these molecules may suppress or promote T-cell proliferation (Fig. 2F-J). Black patients had significantly lower levels of CCL2 and tended to have lower levels of sCD14, neopterin, and IFN- α than patients of other ethnicities (Table 1). CD4Rs tended to have lower sCD14 levels than CD4NRs. Neither IFN- α nor TRAIL plasma levels were associated with Gag-specific T-cell proliferation.

We also assessed the levels of chemokines that direct T-cell and APC migration to the secondary lymphoid organs in steady-state and inflammatory conditions: CCL3, CCL4, CCL21, CXCL10, and CXCL12⁸. Plasma levels of these five chemokines were not related to ethnicity (Table 1). We observed a trend for lower CXCL12 levels in CD4Rs (Fig. 2J). None of the plasma markers were associated with Gag-specific CD4 T cell proliferation after adjustment for ethnicity (Fig 2K).

Gag-specific CD8 T-cell proliferation tends to be associated with lower levels of monocyte activation markers in plasma

A similar analysis was conducted for Gag-specific CD8 T-cell proliferation. CD8Rs tended to have higher levels of mDCs than CD8NRs, by univariate analysis only (Fig.3). CD8Rs had significantly lower plasma concentrations of sCD14 and CCL2 than CD8NRs (Fig. 3F and 3H). CCL2 was not associated with Gag-specific CD8 T-cell proliferation, after adjustment for ethnicity and duration of HIV RNA < 500 copies/ml, but we observed a trend for lower sCD14 (Fig. 3K).

Discussion

The ANRS-EP38-IMMIP focused on the first generation of youths with perinatally acquired HIV-1 infection. We previously reported that Gag-specific CD4 and CD8 T-cell proliferation is more frequent in black patients than in patients from other groups². We now expand these findings by showing that Gag-specific CD4 T-cell proliferation is associated with higher levels of pDCs.

The association between pDC levels and HIV-specific CD4 T-cell proliferation may reflect the *in vivo* cross-talk between innate and adaptive immunity⁹. DC depletion in infected children is similar to that of patients infected as adults¹⁰⁻¹⁴, and these cells had reduced T-cell stimulatory activity^{15, 16}. Upon treatment, viral suppression allows the quantitative and functional restoration of dendritic cells, but to levels usually below those of uninfected controls^{17, 18}. Our data suggest that functional restoration of CD4 HIV-specific T cells may be limited by that of DCs.

In vivo, non-progressive HIV infection is associated with a high capacity of dendritic cells to stimulate T cell proliferation¹⁹. In addition, DCs induce a higher frequency of responding T cells than PBMCs loaded with the same antigen in *in vitro* assays^{20, 21}, and the transduction of APCs with costimulatory molecules enhances HIV-specific T-cell proliferation^{22, 23}. In adults, pDCs and HIV-specific CD8 T-cell frequencies are independent predictors of the viral set-point in the context of planned ART interruption, and the effect of pDCs appears to be related to the presence of HIV-specific CD8 T cells²⁴. However, in our study we observed the association between pDCs and HIV-specific CD4 T-cell proliferation but not between pDCs and HIV-specific CD8 T-cell proliferation.

We report the association between Gag-specific CD4 and CD8 T-cell proliferation and low levels of myeloid cell activation plasma markers. sCD14 exerts an immunoregulatory function: it suppresses mitogen and antigen-specific T-cell proliferation in PBMCs upon binding to the surface of monocytes^{25, 26}. Despite previous reports showing alterations in T-

cell migration in HIV-infected patients ²⁷⁻³⁰, we observed only a modest trend for the association between Gag-specific T cell proliferation and plasma chemokine levels. This may be because T lymphocytes interact with chemokines bound to extracellular matrix molecules or to the surface of endothelial and stromal cells ⁸ or our study lacked sufficient statistical power to detect modest associations.

Finally, we report that youths of black ethnicity have higher levels of dendritic cells and lower levels of activation and inflammation markers than youths of other ethnicities. A study that compared adults from Uganda and the UK found no difference in dendritic cell levels ³¹. However, lower CCL2 levels were reported in African American than in Caucasian patients ³². Both DCs and immune activation levels may contribute to stronger T-cell responses in patients of black ethnicity in our study. This may also be true for other studies that reported stronger HIV or HCV-specific T-cell responses in black individuals than in individuals from other races living in a similar environment ³³⁻³⁶. These differences in plasma CCL2 levels observed between ethnic groups may be related to different frequencies of patients carrying genetic polymorphisms. As an example, the -2581A/G polymorphism in the promoter of the *ccl2* gene affects protein expression is associated with tuberculosis risk in certain ethnic groups ³⁷. Other polymorphisms in the *ccl2* gene coding sequence have been described in West-Africans ³⁸. To the best of our knowledge, the impact of these genetic polymorphisms on the quantification of plasma CCL2 levels by the currently available assays is unknown, and such knowledge would be relevant for further biomarkers studies. Overall, our results suggest that ethnicity may affect the capacity of DCs to produce immune activation molecules and to respond to activation and inflammatory signals.

The strength of our study has been to compare biological differences among patients of various ethnic origins, who shared similar exposure to the virus, access to treatment and environmental factors. This study has some limitations. First, we cannot exclude that some differences in immune restoration may be affected by non-biological factors such as

socioeconomic factors that affect access to care, although there were no major differences in HIV infection history for either ethnic group, as discussed in². Unfortunately, there were no genetic studies, and no HLA-tissue typing, as specific consent is required for genetic investigations in France. We did not include such tests as a requirement for inclusion in the study, as we were concerned that this would have reduced the willingness of subjects to participate. For the biological variables presented in this study, patients from sub-Saharan Africa had values similar to those from patients from the Caribbean, but different from those of patients of other ethnic origins (data not shown). Therefore, these patients were compared to all patients of other ethnicities. The small number of patients in the Caribbean, North Africa and Asia groups precluded their independent analysis. Finally, this was an exploratory analysis; the sample size was sufficient for the results to be conclusive for some but not all immune parameters tested.

We provide new information on higher dendritic levels related to both the black ethnic background and the recovery of HIV-specific CD4 T-cell proliferation under cART. Our results highlight the need to expand our knowledge on the impact of ethnicity on immune-mediated clinical events, such as the immune reconstitution syndrome, and on potentially useful immune markers for clinical management, such as sCD14.

Competing interests

The authors have no competing interests to declare.

Acknowledgments and funding

Peptides were provided by the NIH AIDS Research and Reference Reagent Program. We thank all the patients who agreed to participate in this study. We would also like to thank the nurses and staff members from the various clinical sites. We thank Sandrine Leveillé (Hôpital Robert Debré), Geneviève Vaudre (Hôpital Trousseau), Sylvie Tassi (Hôpital Jean Verdier), Nora Boudjoudi (Hôpital Port Royal), Marie-Christine Mourey (Hôpital Necker), Thierry Wack (CESP INSERM U1018), Yassine Benmebarek and Naima Bouallag-Bonnet (former members of CESP INSERM U1018). We thank Yves Rivière for his role in this collaborative work. We would also like to thank Elisabeth Monchâtre, Pauline Louche and Céline Clairet for expert technical assistance. This text has been verified by a native English speaker.

This work was supported by the 2006-232 and 2009-165 grants from the “Agence Nationale de recherche sur le SIDA et les Hépatites” (ANRS, www.anrs.fr) and by the “Fondation AREVA” (<http://www.areva.com/FR/groupe-910/fondation-implication-societale-pour-un-developpement-durable.html>). The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.

Footnotes

The institutions and investigators of the ANRS-EP38-IMMIP Study were: Pédiatrie-néonatalogie, Hôpital Louis Mourier, Colombes (Corinne Floch-Tudal); Gynécologie-Obstétrique, Groupe Hospitalier Cochin Tarnier-Port-Royal, Paris (Ghislaine Firtion); Pédiatrie-Centre Hospitalier Intercommunal, Créteil (Sophie Lemerle); Pédiatrie-Centre Hospitalier Intercommunal, Villeneuve Saint-Georges (Anne Chace); Immuno-Hématologie Pédiatrique, Groupe Hospitalier Necker-Enfants Malades, Paris (Stéphane Blanche, Florence Veber); Pédiatrie, Centre Hospitalier Sud-Francilien, Evry (Adrien May); Maladies

Infectieuses, Hôpital Jean Verdier, Bondy (Vincent Jeantils); Onco-Hématologie Pédiatrique Hôpital Trousseau, Paris (Catherine Dollfus); Pédiatrie-Hôpital Robert Debré, Paris (Martine Levine, Albert Faye); Centre de Diagnostic et de Thérapeutique, Hôpital de l'Hôtel-Dieu, Paris (Jean-Paul Viard).

Additional files

SupplementaryData_ARHR.docx contains Supplementary Table 1.

References

1. Deeks, SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
2. Le Chenadec, J, Scott-Algara D, Blanche S, et al. Gag-specific CD4 and CD8 T-cell proliferation in adolescents and young adults with perinatally acquired HIV-1 infection is associated with ethnicity - The ANRS-EP38-IMMIP study. PLoS One 2015; 10:e0144706.
3. Manches, O, Frleta D, Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends Immunol 2014; 35:114-122.
4. Avettand-Fenoel, V, Blanche S, Le Chenadec J, et al. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP Study. J Infect Dis 2012; 205:1520-1528.
5. Blanche, S, Scott-Algara D, Le Chenadec J, et al. Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in French adolescents and young adults infected in the perinatal period: The ANRS-EP38-IMMIP study. Clin Infect Dis 2014; 58:573-587.
6. Blank, SE, Johnson EC, Weeks DK, Wysham CH. Circulating dendritic cell number and intracellular TNF-alpha production in women with type 2 diabetes. Acta Diabetol 2012; 49:25-32.
7. Orsini, G, Legitimo A, Failli A, Massei F, Biver P, Consolini R. Enumeration of human peripheral blood dendritic cells throughout the life. International Immunology 2012; 24:347-356.
8. Bromley, SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008; 9:970-980.
9. Swiecki, M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015; 15:471-485.

10. Azzoni, L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, Montaner LJ. Dendritic and natural killer cell subsets associated with stable or declining CD4 cell counts in treated HIV-1-infected children. J Infect Dis 2005; 191:1451-1459.
11. Zhang, Z, Fu J, Zhao Q, et al. Differential restoration of myeloid and plasmacytoid dendritic cells in HIV-1-infected children after treatment with highly active antiretroviral therapy. J Immunol 2006; 176:5644-5651.
12. Badolato, R, Ghidini C, Facchetti F, et al. Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion. J Transl Med 2008; 6.
13. Usuga, X, Montoya CJ, Landay AL, Rugeles MT. Characterization of quantitative and functional innate immune parameters in HIV-1-infected Colombian children receiving stable highly active antiretroviral therapy. JAIDS 2008; 49:348-357.
14. Selvaraj, A, Pilakka-Kanthikeel S, Bhavani PK, Hanna LE, Pahwa S, Swaminathan S. Defective dendritic cell response to Toll-like receptor 7/8 agonists in perinatally HIV-infected children. Pathog Dis 2013; 69:184-193.
15. Chougnet, C, Kovacs A, Baker R, et al. Influence of human immunodeficiency virus-infected maternal environment on development of infant interleukin-12 production. J Infect Dis 2000; 181:1590-1597.
16. Hughes, SM, Amadi B, Mwiya M, Nkamba H, Tomkins A, Goldblatt D. Dendritic cell anergy results from endotoxemia in severe malnutrition. J Immunol 2009; 183:2818-2826.
17. Chehimi, J, Azzoni L, Farabaugh M, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol 2007; 179:2642-2650.
18. Altfeld, M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 2011; 11:176-186.

19. Huang, JH, Burke PS, Cung TDH, et al. Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol 2010; 84:9463-9471.
20. Betts, MR, Price DA, Brenchley JM, et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 2004; 172:6407-6417.
21. Huang, XL, Fan Z, Borowski L, Rinaldo CR. Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells. Clin Vacc Immunol 2009; 16:1504-1516.
22. Bukczynski, J, Wen T, Wang C, et al. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol 2005; 175:6378-6389.
23. De Keersmaecker, B, Heirman C, Corthals J, et al. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol 2011; 89:989-999.
24. Papasavvas, E, Foulkes A, Yin XF, et al. Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1+ patients. Immunology 2015; 145:380-390.
25. Lue, KH, Lauener RP, Winchester RJ, Geha RS, Vercelli D. Engagement of CD14 on human monocytes terminates T-cell proliferation by delivering a negative signal to T cells. J Immunol 1991; 147:1134-1138.
26. Rey-Nores, JE, Bensussan A, Vita N, et al. Soluble CD14 acts as a negative regulator of human T cell activation and function. Eur J Immunol 1999; 29:265-276.
27. Combadière, B, Faure S, Autran B, Debré P, Combadière C. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS 2003; 17:1279-1290.

28. Brainard, DM, Tager AM, Misdraji J, et al. Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction. J Virol 2007; 81:8439-8450.
29. Meditz, AL, Schlichtemeier R, Folkvord JM, et al. SDF-1 alpha is a potent inducer of HIV-1-specific CD8+ T-cell chemotaxis, but migration of CD8+ T cells is impaired at high viral loads. AIDS Res Hum Retrovir 2008; 24:977-985.
30. Perez-Patrigeon, S, Vingert B, Lambotte O, et al. HIV infection impairs CCR7-dependent T-cell chemotaxis independent of CCR7 expression. AIDS 2009; 23:1197-1207.
31. Jones, GJ, Watera C, Patterson S, et al. Comparative loss and maturation of peripheral blood dendritic cell subpopulations in African and non-African HIV-1-infected patients. AIDS 2001; 15:1657-1663.
32. Shebl, FM, Yu K, Landgren O, Goedert JJ, Rabkin CS. Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retrovir 2012; 28:809-815.
33. Sugimoto, K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37:590-599.
34. Sharp, ER, Barbour JD, Karlsson RK, et al. Higher frequency of HIV-1-specific T cell immune responses in African American children vertically infected with HIV-1. J Infect Dis 2005; 192:1772-1780.
35. Golden-Mason, L, Klarquist J, Wahed AS, Rosen HR. Programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: Race-dependent differences. J Immunol 2008; 180:3637-3641.
36. Perez-Losada, M, Posada D, Arenas M, et al. Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. Retrovirology 2009; 6:67.
37. Zhang, Y, Zhang J, Zeng L, et al. The -2518A/G polymorphism in the *MCP-1* gene and tuberculosis risk: A meta-analysis. PLoS One 2012; 7:e38918.

38. Thye, T, Nejentsev S, Intemann CD, et al. MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa. Hum Mol Genet 2009; 18:381-388.